Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL

Key Points

• Quantinno Capital Management increased its Replimune position by 782.7% in the first quarter, owning 108,477 shares valued at approximately $830,000. Institutional investors collectively hold 92.53% of the company.
• Analyst sentiment has improved, with several firms upgrading the stock; Replimune has a consensus “Moderate Buy” rating and an average price target of $11.86.
• Replimune shares opened at $14.63, near their 12-month high of $15.70, while the company reported a quarterly loss of $0.72 per share, slightly below the $0.69 consensus estimate. Recent insider stock sales were made to cover tax withholding obligations tied to equity awards.

Quantinno Capital Management LP boosted its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 782.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 108,477 shares of the company's stock after buying an additional 96,188 shares during the quarter. Quantinno Capital Management LP owned approximately 0.13% of Replimune Group worth $830,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new stake in shares of Replimune Group during the 4th quarter worth about $29,000. Russell Investments Group Ltd. grew its position in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock valued at $33,000 after acquiring an additional 7,569 shares during the period. CWM LLC increased its stake in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company's stock valued at $39,000 after purchasing an additional 2,886 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company's stock valued at $58,000 after purchasing an additional 6,873 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Replimune Group in the 2nd quarter valued at about $69,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Insider Activity at Replimune Group

In other news, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the sale, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. This represents a 4.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $98,987.04. Following the completion of the sale, the chief accounting officer owned 99,425 shares of the company's stock, valued at $1,289,542.25. This trade represents a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 81,868 shares of company stock worth $1,017,068 over the last 90 days. Corporate insiders own 5.40% of the company's stock.

Wall Street Analysts Forecast Growth

REPL has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Replimune Group from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 23rd. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research report on Friday, August 7th. BMO Capital Markets raised Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 target price for the company in a research note on Tuesday, June 30th. Piper Sandler upgraded Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 31st. Finally, Leerink Partners raised shares of Replimune Group from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $11.86.

Replimune Group Price Performance

Shares of Replimune Group stock opened at $14.63 on Tuesday. The business has a 50 day simple moving average of $10.77 and a two-hundred day simple moving average of $7.84. Replimune Group, Inc. has a 12 month low of $1.50 and a 12 month high of $15.70. The stock has a market capitalization of $1.23 billion, a P/E ratio of -4.64 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). As a group, analysts predict that Replimune Group, Inc. will post -2.7 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source